L-carnitine as an adjunct treatment for septic shock patients with acute kidney injury: a multicentre, randomized, 2-parallel group, superiority trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512508-21-00

Enrollment

272

Registered

2024-04-26

Start date

2018-01-12

Completion date

Unknown

Last updated

2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

shock septic

Brief summary

Mortality

Detailed description

Mortality, Survival (verification of vital status and collection of death certificates to determine date of death), Days alive and not on renal replacement therapy, Days alive and free of renal failure, Days alive and free of organ failure, Days alive and not on mechanical ventilation, Days alive and not in ICU, Days alive and not in hospital, Days alive and free of catecholamines

Interventions

DRUGSODIUM CHLORIDE

DRUGLEVOCARNITINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mortality	—

Secondary

Measure	Time frame
Mortality, Survival (verification of vital status and collection of death certificates to determine date of death), Days alive and not on renal replacement therapy, Days alive and free of renal failure, Days alive and free of organ failure, Days alive and not on mechanical ventilation, Days alive and not in ICU, Days alive and not in hospital, Days alive and free of catecholamines	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026